The effect of simvastatin on glucose homeostasis in streptozotocin induced type 2 diabetic rats

Journal of Diabetes Research

Volumn 2013, Issue , 2013, Pages

  Wang, Lulu ^a   Duan, Guanglan ^a   Lu, Yong ^a   Pang, Shuguang ^a   Huang, Xianping ^a   Jiang, Qiang ^a   Dang, Ningning ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FLUID INTAKE; FOOD INTAKE; GLUCOSE HOMEOSTASIS; HYPERGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBSERVATIONAL STUDY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

EID: 84879343587     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2013/274986     Document Type: Article

References (31)

1. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C. E., Pan C., Poulter N., Rodgers A., Williams B., Bompoint S., De Galan B. E., Travert F., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine 2008 358 24 2560 2572 10.1056/NEJMoa0802987 (Pubitemid 351831357)
2. Cholesterol Treatment Trialists' (CTT) Collaborators, Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet 2008 371 9607 117 125 2-s2.0-38049033935 10.1016/S0140-6736(08)60104-X
3. Liao J. K., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Current Atherosclerosis Reports 2009 11 4 243 244
4. Cannon C. P., Steinberg B. A., Murphy S. A., Mega J. L., Braunwald E., Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Journal of the American College of Cardiology 2006 48 3 438 445 2-s2.0-33746355566 10.1016/j.jacc.2006.04.070 (Pubitemid 44109954)
5. Kumai T., Matsumoto N., Koitabashi Y., Takeba Y., Oonuma S., Sekine S., Tadokoro M., Kobayashi S., Pleiotropic effects of 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels. Current Medicinal Chemistry 2005 3 3 195 201 2-s2.0-22144475853 10.2174/1568016054368223 (Pubitemid 40974780)
6. Ma T., Chang M.-H., Tien L., Liou Y.-S., Jong G.-P., The long-term effect of statins on the risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective longitudinal cohort study. Drugs and Aging 2012 29 1 45 51 10.2165/11597250-000000000-00000
7. Jula A., Marniemi J., Huupponen R., Virtanen A., Rastas M., Rönnemaa T., Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 2002 287 5 598 605 2-s2.0-0037028782 (Pubitemid 34252011)
8. Ohmura C., Watada H., Hirose T., Tanaka Y., Kawamori R., Acute onset and worsening of diabetes concurrent with administration of statins. Endocrine Journal 2005 52 3 369 372 2-s2.0-22344444464 10.1507/endocrj.52.369 (Pubitemid 41003529)
9. Gannagé-Yared M. H., Azar R. R., Amm-Azar M., Khalifé S., Germanos-Haddad M., Neemtallah R., Halaby G., Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 2005 54 7 947 951 2-s2.0-20444497396 10.1016/j.metabol.2005.02.011 (Pubitemid 40827213)
10. Koh K. K., Quon M. J., Han S. H., Chung W.-J., Ahn J. Y., Seo Y.-H., Choi I. S., Shin E. K., Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. Journal of the American College of Cardiology 2005 45 10 1649 1653 10.1016/j.jacc.2005.02.052 (Pubitemid 40704501)
11. Kwang K. K., Quon M. J., Seung H. H., Chung W. J., Jeong Y. A., Seo Y. H., Moon H. K., Tae H. A., In S. C., Eak K. S., Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004 110 24 3687 3692 2-s2.0-20844456215 10.1161/01.CIR.0000143085.86697.13 (Pubitemid 39665258)
12. Güçlü F., Özmen B., Hekimsoy Z., Kirmaz C., Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomedicine and Pharmacotherapy 2004 58 10 614 618 10.1016/j.biopha.2004.09.005 (Pubitemid 40260386)
13. Okada K., Maeda N., Kikuchi K., Tatsukawa M., Sawayama Y., Hayashi J., Pravastatin improves insulin resistance in dyslipidemic patients. Journal of Atherosclerosis And thrombosis 2005 12 6 322 329 2-s2.0-33644872862
14. Nakata M., Nagasaka S., Kusaka I., Matsuoka H., Ishibashi S., Yada T., Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006 49 8 1881 1892 2-s2.0-33745794259 10.1007/s00125-006-0269-5 (Pubitemid 44025043)
15. Ginter E., Simko V., Statins: the drugs for the 21st century? Bratislavské Lekárske Listy 2009 110 10 664 668 2-s2.0-74049157745
16. Epstein M., Campese V. M., Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors on renal function. American Journal of Kidney Diseases 2005 45 1 2 14 2-s2.0-11144322775 10.1053/j.ajkd.2004.08.040 (Pubitemid 40038040)
17. Malcolm J., Meggison H., Sigal R., Prevention of cardiovascular events in diabetes. Clinical Evidence 2003 10 690 714 2-s2.0-16544364737
18. Lalli C. A., Pauli J. R., Prada P. O., Cintra D. E., Ropelle E. R., Velloso L. A., Saad M. J. A., Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet. Metabolism 2008 57 1 57 65 2-s2.0-36849086456 10.1016/j.metabol.2007.07.021 (Pubitemid 350234973)
19. Takagi T., Matsuda M., Abe M., Kobayashi H., Fukuhara A., Komuro R., Kihara S., Caslake M. J., McMahon A., Shepherd J., Funahashi T., Shimomura I., Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008 196 1 114 121 2-s2.0-38049004875 10.1016/j. atherosclerosis.2007.02.013
20. Sugiyama S., Fukushima H., Kugiyama K., Maruyoshi H., Kojima S., Funahashi T., Sakamoto T., Horibata Y., Watanabe K., Koga H., Sugamura K., Otsuka F., Shimomura I., Ogawa H., Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007 194 2 e43 e51 2-s2.0-34548500220 10.1016/j.atherosclerosis.2006.08.023 (Pubitemid 47513070)
21. Costa A., Casamitjana R., Casals E., Álvarez L., Morales J., Masramón X., Hernández G., Gomis R., Conget I., Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabetic Medicine 2003 20 9 743 745 2-s2.0-0642336164 10.1046/j.1464-5491.2003.00993.x (Pubitemid 41701469)
22. Szendroedi J., Anderwald C., Krssak M., Bayerle-Eder M., Esterbauer H., Pfeiler G., Brehm A., Nowotny P., Hofer A., Waldhausl W., Roden M., Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. Diabetes Care 2009 32 2 209 214 2-s2.0-61849172978 10.2337/dc08-1123
23. Sukhija R., Prayaga S., Marashdeh M., Bursac Z., Kakar P., Bansal D., Sachdeva R., Kesan S. H., Mehta J. L., Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. Journal of Investigative Medicine 2009 57 3 495 499 2-s2.0-67650702822 10.231/JIM.0b013e318197ec8b
24. Collins R., Armitage J., Parish S., Sleight P., Peto R., MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. The Lancet 2002 360 9326 7 22 2-s2.0-0037031061 10.1016/S0140-6736(02)09327-3 (Pubitemid 34756487)
25. Sattar N., Preiss D., Murray H. M., Welsh P., Buckley B. M., de Craen A. J., Seshasai S. R. K., McMurray J. J., Freeman D. J., Jukema J. W., Macfarlane P. W., Packard C. J., Stott D. J., Westendorp R. G., Shepherd J., Davis B. R., Pressel S. L., Marchioli R., Marfisi R. M., Maggioni A. P., Tavazzi L., Tognoni G., Kjekshus J., Pedersen T. R., Cook T. J., Gotto A. M., Clearfield M. B., Downs J. R., Nakamura H., Ohashi Y., Mizuno K., Ray K. K., Ford I., Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet 2010 375 9716 735 742 2-s2.0-77549087054 10.1016/S0140- 6736(09)61965-6
26. Ridker P. M., Danielson E., Fonseca F. A. H., Genest J., Gotto Jr. A. M., Kastelein J. J. P., Koenig W., Libby P., Lorenzatti A. J., MacFadyen J. G., Nordestgaard B. G., Shepherd J., Willerson J. T., Glynn R. J., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine 2008 359 21 2195 2207 10.1056/NEJMoa0807646
27. Bianchi C., Penno G., Miccoli R., Del Prato S., Blood glucose control and coronary heart disease. Herz 2010 35 3 148 159 2-s2.0-77952825779 10.1007/s00059-010-3340-4
28. Chamberlain L. H., Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Letters 2001 507 3 357 361 2-s2.0-0035798232 10.1016/S0014-5793(01)03007-1 (Pubitemid 33030265)
29. Mabuchi H., Higashikata T., Kawashiri M., Katsuda S., Mizuno M., Nohara A., Inazu A., Koizumi J., Kobayashi J., Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. Journal of Atherosclerosis and Thrombosis 2005 12 2 111 119
30. Sasaki J., Iwashita M., Kono S., Statins: beneficial or adverse for glucose metabolism. Journal of Atherosclerosis and Thrombosis 2006 13 3 123 129 2-s2.0-33749046325
31. Nielson C., Lange T., Hadjokas N., Blood glucose and coronary artery disease in nondiabetic patients. Diabetes Care 2006 29 5 998 1001 2-s2.0-33746342154 10.2337/diacare.295998 (Pubitemid 44115234)